Therapeutic antibodies

Question 1

Alemtuzumab

Answer 1

Targets CD52

Treats CLL (“alymtuzumab”)

Question 2

Bevacizumab

Answer 2

Targets VEGF

Treats colorectal cancer, RCC

Question 3

Cetuximab

Answer 3

Targets EGFR

Treats stage IV colorectal cancer, head and neck cancer

Question 4

Rituximab

Answer 4

Targets CD20

Treats B-cell non-Hodgking lymphoma, RA, ITP

Question 5

Trastuzumab (Herceptin)

Answer 5

Targets Her2/neu

Treats breast cancer and gastric cancer

Question 6

Infliximab, Adalimumab

Answer 6

Targets TNF-a

Treats IBD, RA, ankylosing spondylitis, psoriasis

RA “inflix” pain in “da limbs”

Question 7

Natalizumab

Answer 7

Targets a4-integrin (leukocyte adhesion)

Treats MS and Crohn disease

Risk of PML in patients with JC virus

Question 8

Abciximab

Answer 8

Targets Gb IIb/IIIa

Anti-platelet agent for prevention of ischemic complications in patients undergoing percutaneous coronary interventions

IIb x IIIa = absiximab

Question 9

Denosumab

Answer 9

Targets RANKL

Treats osteoporosis (inhibits osteoclast maturation, mimics osteoprotegrin)

Denosumab affects osteoclasts

Question 10

Digoxin immune Fab

Answer 10

Targets digoxin

Antidote for digoxin toxicity

Question 11

Omalizumab

Answer 11

Targets IgE

Treats allergic asthma by preventing IgE from binding to FceRI, a high-affinity IgE receptor constitutively expressed on mast cells and basophils

Question 12

Palivizumab

Answer 12

Targets RSV F protein

RSV PPx for high-risk infants

“Palivizumab - virus”